《现代医学与健康研究》编辑部官网!【中国医师协会系列期刊】
乳腺癌组织中 PD-L1、IMP3 表达水平与患者临床病理学特征、术后复发的关系
DOI:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R737.9

基金项目:

江西省卫生健康委员会科技计划项目(编号:20204844)


Relationship among the expression levels of PD-L1 and IMP3 in breast cancer tissues, the clinicopathological characteristics of patients and postoperative recurrence
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的 分析程序性死亡受体-?配体 1(PD-L1)、胰岛素样生长因子Ⅱ mRNA 结合蛋白 3(IMP3)在乳腺癌组织中的表达情况,探究其与患者临床病理学特征、术后复发的关系。方法 回顾性分析 2015 年 1 月至 2021 年 3 月吉安市妇幼保健院和吉安市中心人民医院收治的 102 例乳腺浸润性癌患者的临床资料,收集患者癌组织病理标本,采用 SP 法免疫组织化学染色检测病理组织 PD-L1、IMP3 表达情况,分析 PD-L1、IMP3 表达水平与患者临床病理学特征、术后复发的关系。结果 102 例乳腺癌病理组织标本中 PD-L1、IMP3 的阳性表达率分别为 57.84%、19.61%;IMP3 在不同分子分型乳腺癌患者病理组织中的阳性表达率从高到低依次为 Basal-like 型(66.67%)、Luminal B 型 [ 人表皮生长因子受体 -2(HER-2)阳性 ](17.24%)、HER-2 过表达型(15.38%)、Luminal A 型(14.29%)、Luminal B型(HER-2 阴性)(10.00%)(均P < 0.05);且合并坏死的乳腺癌组织中 IMP3 阳性表达率(33.33%)显著高于未合并坏死者(14.67%) (P < 0.05);随着乳腺癌患者术后复发风险级别的逐渐升高,乳腺癌组织中 PD-L1、IMP3 阳性表达率逐渐升高,但组间比较,差异均无统计学意义(均P > 0.05);经Spearman 等级相关分析显示,乳腺癌组织中 PD-L1 与 IMP3 阳性表达呈正相关性(r = 0.172),但差异无统计学意义(P > 0.05)。结论 乳腺癌病理组织 PD-L1、IMP3 水平呈高表达,尤其在三阴性乳腺癌病理组织中表达水平最高,且IPM3 阳性表达及其表达水平变化与乳腺肿瘤患者的不良预后和进展有关,而 PD-L1 的阳性表达及其表达变化与肿瘤的不良预后和进展无关,且两者间阳性表达亦无明显相关性。

    Abstract:

    Objective Analyzed the expression of programmed death receptor- ligand 1 (PD-L1), insulin-like growth factor Ⅱ mRNA binding protein 3 (IMP3) in breast cancer tissues, explored the relationship among them and patients' clinicopathological characteristics and postoperative recurrence. Methods Retrospectively analysed the clinical datas of 102 patients with invasive breast cancer admitted to the department of pathology of Ji'an Maternal and Child Health Hospital and Ji'an Central People's Hospital from January 2015 to March 2021, the pathological specimens of cancer tissues from patients were collected, and the expression of PD-L1 and IMP3 in pathological tissues were detected used by SP immunohistochemical staining method, the relationship among the PD-L1 and IMP3 expression levels, clinicopathological characteristics and postoperative recurrence of patients. Results The positive expression rates of PD-L1 and IMP3 among 102 cases breast cancer pathological tissue specimens were 57.84% and 19.61% respectively; the the positive expression rate of IMP3 in the pathological tissues of breast cancer patients with different molecular types from high to low were Basal-like (66.67%), Luminal B type [Human epidermal growth factor receptor-2 (HER-2) positive] (17.24%), HER-2 overexpression type (15.38%), Luminal type A (14.29%), Luminal B type (HER-2 negative) (10.00%) in order (all P < 0.05); and the positive expression rate of IMP3 in breast cancer tissues with necrosis (33.33%) was significantly higher than that in those without necrosis (14.67%) (P < 0.05); with the gradual increase in the risk of recurrence in breast cancer patients after surgery, the positive expression rate of PD-L1 and IMP3 in breast cancer tissues gradually increased, but comparing between groups, the difference was without statistical significance (all P > 0.05); Spearman rank correlation analysis showed that, there was a positive correlation between the positive expression of PD-L1 and IMP3 in breast cancer tissues (r = 0.172), but difference was without statistical significance (P > 0.05). Conclusion The levels of PD-L1 and IMP3 in breast cancer pathological tissues are highly expressed, especially in the pathological tissues of triple-negative breast cancer, the expression level is highest, and the positive expression of IPM3 and the expression level changes are related to the poor prognosis and progression of breast cancer patients, while the positive expression of PD-L1 and the expression level changes are not related to the poor prognosis and progression of breast cancer patients, and there is no obvious correlation between the positive expression of PD-L1 and IPM3 .

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-09-06
  • 出版日期:

地址:北京朝阳区北沙滩1号16信箱

邮编:100083

电话:010-64882183 64883630

E-mail:xdyx2020@vip.163.com


温馨提示:建议您使用Chrome80、火狐74+、IE11浏览器 ,当您的浏览器版本过低,可能会影响部分功能正常使用。

现代医学与健康研究 ® 2024 版权所有

技术支持:北京勤云科技发展有限公司